Landfar Bio-medicine Co., Ltd operates as a biomedical technology company. It operates in two segments, Biomedicine, and Energy Saving and Environmental Protect...
Norstella Launches Pipeline-to-Patient Productivity Index to Benchmark Biopharma Performance Across the Drug Development Lifecycle
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
ST Landfar plans to acquire 51% equity of Huize Pharmaceutical, which is expected to constitute a significant asset restructuring situation
Overview of the lifting of restrictions on the sale of A-shares | July 10
ST Landfar plans to list the sale of a 52% stake in its subsidiary Nanhua Heping
The ST sector strengthened, with over 20 stocks hitting the daily limit up